齐鲁晚报·齐鲁壹点 张文珂 根据赛迪顾问统计，截至2024年7月31日，全国共有30个省（区、市）发布化工园区认定名单，共认定化工园区745家。其中，山东 以84家位居首位，浙江、河南、湖北、安徽等省份均在40家以上。 齐鲁晚报·齐鲁壹点梳理发现，山东共有16家化工园区入围该项榜单，数量位居全国第一。其中，东营、淄博、潍坊、青岛4市分别 入围5家、3家、2家、2家，烟台、济宁、滨州、菏泽4市各入围1家。 | 排名 | 园区名称 | 省 (市、 | 城市 | 排名 | 园区名称 | 省 (市) | 城市 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 区) | | | | 区) | | | 1 | 上海化学工业区 | 上海 | 上海 | 51 | 博兴化工产业园 | 山东 | 滨州 | | 2 | 惠州大亚湾石化产业园区 | 广东 | 惠州 | 52 | 辽阳重要芳烃及化纤原料基地 | 辽宁 | 辽阳 | | 3 | 宁波石化经济技术开发区 | 浙江 | 宁波 | 53 | 茂名茂南石化工业园 | 广东 | 茂名 | | ব | 齐鲁化学工业区 ...

Core Insights - The Huizhou New Materials Industrial Park has attracted a total of 36 projects with a cumulative investment of 47.6 billion yuan, focusing on high-end plasticizers and electronic chemicals in 2025 [1] Group 1: Strategic Positioning - The park aims to become a leading new materials industrial base in China and an innovation hub for new materials technology in the Guangdong-Hong Kong-Macao Greater Bay Area, leveraging raw material resource advantages [1] - The industrial park is concentrating on downstream petrochemical industries such as high-end polyolefins and semiconductor materials, accelerating the aggregation along the complete industrial chain from C2 to aromatics [1] Group 2: Project Highlights - In the first half of the year, the signed electronic chemical projects focus on semiconductor packaging materials and display panel materials, further strengthening the electronic new materials industry cluster led by Bailihong Shengda and Xingfu Electronics [1] - A key project for the first half of 2025 is the Guangdong Lichuang Chemical New Materials Co., Ltd. project, with a total investment of 2.56 billion yuan, producing 180,000 tons/year of phthalic anhydride and 800,000 tons/year of various plasticizers, expected to become the largest plasticizer production base in China with an estimated annual output value of 8.8 billion yuan [1]

根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露：第十三 号——化工》有关规定，现将浙江建业化工股份有限公司（以下简称"公司"）2025 年上半年主要经营数据披露如下： 浙江建业化工股份有限公司 2025 年上半年主要经营数据公告 证券代码：603948 证券简称：建业股份 公告编号：2025-015 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 2025 年 1-6 月 | 2025 年 1-6 月 | 2025 年 1-6 月 | | --- | --- | --- | --- | | | 产量（吨） | 销量（吨） | 销售金额（万元） | | 低碳脂肪胺 | 57966.63 | 57666.74 | 67986.01 | | 增塑剂 | 22054.96 | 21720.28 | 15525.66 | | 乙酸酯 | 18614.31 | 18708.22 | 12030.25 | | 电子化学品 | 3235.80 | 2657.15 | 1718.33 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完 ...

塑料助剂又叫塑料添加剂，是聚合物（合成树脂）进行成型加工时为改善其加工性能或为改善树脂本身性能所不足而必须添加的一些化合物。 中国产业研究报告网发布的《2025-2031年中国塑料助剂市场研究与战略咨询报告》共十六章。首先介绍了塑料助剂行业市场发展环境、塑料助剂整体运行 态势等，接着分析了塑料助剂行业市场运行的现状，然后介绍了塑料助剂市场竞争格局。随后，报告对塑料助剂做了重点企业经营状况分析，最后分析了塑 料助剂行业发展趋势与投资预测。您若想对塑料助剂产业有个系统的了解或者想投资塑料助剂行业，本报告是您不可或缺的重要工具。 本研究报告数据主要采用国家统计数据，海关总署，问卷调查数据，商务部采集数据等数据库。其中宏观经济数据主要来自国家统计局，部分行业统计数据 主要来自国家统计局及市场调研数据，企业数据主要来自于国统计局规模企业统计数据库及证券交易所等，价格数据主要来自于各类市场监测数据库。 报告目录： 第一部分 产业环境透视 第一章 中国塑料助剂行业发展概述 第一节 塑料助剂的内涵 一、塑料助剂定义 二、塑料助剂功能 三、塑料助剂应用 四、塑料助剂分类 1、助剂来源分类 2、助剂功效分类 五、塑料助剂特性 1 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号——化工》、《关 于做好主板上市公司 2025 年半年度报告披露工作的重要提醒》的要求，广东天 安新材料股份有限公司（以下简称"公司"）现将 2025 年半年度高分子复合饰 面材料业务主要经营数据披露如下： 二、高分子复合饰面材料主要产品的价格变动情况（不含税） | 主要产品 | 2025 | 年 1-6 | 月平均售 | 2024 | 年 1-6 | 月平均 | 半年度均 价同比变 | 季度均价环比 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 价 | | | 售价 | | 动比率（%） | 变动比率（%） | | | 家居装饰 | | 23,184.42 | 元/吨 | | 25,292.04 | 元/吨 | -8.33 | | -1.15 | | 饰面材料 | | | | | | | | | | 一、2025 年 1-6 月高 ...

Core Viewpoint - The article discusses an innovative method for chemically recycling mixed plastic waste into valuable chemical products, addressing the environmental challenges posed by plastic waste [2][3]. Group 1: Research Overview - The research, published in Nature, presents a strategy to convert eight common types of plastic waste into their original chemical components or other valuable compounds [3][10]. - The method focuses on identifying functional groups in mixed plastic waste to facilitate the separation and conversion of these materials into useful products [5][8]. Group 2: Methodology - The research team developed a solid-state NMR method to accurately identify the types of plastics present in the mixed waste, which is crucial for the subsequent processing steps [5][6]. - By using selective solvents, the team was able to dissolve and separate specific plastics from the mixed waste, followed by catalytic processes to convert these plastics into valuable products [6][7]. Group 3: Results and Innovations - The study successfully demonstrated the feasibility of the proposed strategy using a real-life plastic mixture, yielding various chemical substances such as benzoic acid, plasticizers, and hydrocarbons [7][8]. - The key innovation lies in the universal strategy designed to tackle the challenge of chemical recycling of mixed plastics, allowing for adjustments in chemical steps based on the initial identification of major components [8][10].

Group 1 - The core point of the news is the change in the indirect controlling shareholder of Bluestar Medical, with Langhui Petrochemical acquiring a 52.0395% stake, diluting Bluestar Group's stake from 98% to 47.0013% [1] - The company emphasizes that this equity change does not trigger a mandatory takeover, nor does it lead to a change in the controlling shareholder or actual controller, and it will not adversely affect the company's business structure or financial status [1][2] - Langhui Petrochemical, previously a subsidiary of Bluestar Medical, has maintained a close cooperative relationship with the company, being its largest supplier for three consecutive years from 2022 to 2024 [2][3] Group 2 - Langhui Petrochemical initiated its listing guidance in September 2021, with the latest guidance period set from January 1 to March 31, 2025, but faces challenges in internal control and independent director appointments [3] - Bluestar Medical has experienced continuous pressure on its performance over the past three years, with revenues of 4.9 billion, 4.93 billion, and 6.25 billion from 2022 to 2024, and net profits of -372 million, -568 million, and -445 million during the same period [4] - As of May 28, Bluestar Investment holds 235 million shares of Bluestar Medical, accounting for 23.31%, with 183 million shares pledged, representing 18.2% of the total share capital [4]

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]

Core Viewpoint - The report outlines the equity change in Lanfang Medical Co., Ltd. due to Shandong Langhui Petrochemical Co., Ltd. increasing its stake to 52.0395% in Lanfang Investment, resulting in a dilution of Lanfang Group's shareholding from 98% to 47.0013% [1][2][16]. Group 1: Equity Change Details - Shandong Langhui's investment in Lanfang Investment was made through a capital increase, where it converted its debt of RMB 109,096.0961 million into equity [20][21]. - The registered capital of Lanfang Investment increased from RMB 89,600 million to RMB 186,820.4058 million, with RMB 97,220.4058 million allocated to registered capital and RMB 11,875.6903 million to capital reserves [18][19]. - The equity change was executed without any other shareholders exercising their preemptive rights [19]. Group 2: Financial Overview of Shandong Langhui - As of the report date, Shandong Langhui's total assets were RMB 494,725.12 million, with total liabilities of RMB 336,848.50 million, resulting in net assets of RMB 157,876.62 million [10]. - The company's revenue for the year 2024 was RMB 1,341,548.59 million, with a net profit of RMB 21,266.65 million [10]. - The net asset return rate was 13.47%, and the asset-liability ratio stood at 68.09% [10]. Group 3: Business Operations and Independence - Shandong Langhui specializes in the research, production, and sales of fine chemicals, primarily producing plasticizers and PVC resin products [9][12]. - The equity change will not affect Lanfang Medical's independence in operations, assets, personnel, finance, and business [24][25]. - Shandong Langhui has committed to maintaining the independence of Lanfang Medical and avoiding any interference in its operations [24][25]. Group 4: Future Plans and Commitments - Shandong Langhui has no plans to further increase or dispose of its shares in Lanfang Medical within the next 12 months following the equity change [16][22]. - There are no plans for significant adjustments to Lanfang Medical's main business, asset restructuring, or changes in management within the next year [22][23]. - Shandong Langhui has pledged to avoid any competition with Lanfang Medical and its subsidiaries [27][28].

Core Viewpoint - The article discusses the health risks associated with plastic additives, emphasizing the difficulty of completely avoiding plastic in daily life while advocating for informed choices to mitigate exposure risks [1][2]. Group 1: Understanding Plastic Additives - Plastic additives are essential for enhancing the properties of plastics, with 6% of plastic composition being additives, while 94% consists of polymers [2][4]. - Common additives include plasticizers, flame retardants, bisphenol A (BPA), and per- and polyfluoroalkyl substances (PFAS), which are prevalent in everyday products [6][12]. Group 2: Health Risks of Specific Additives - BPA is widely used in polycarbonate plastics and epoxy resins, posing risks such as developmental issues in children and reproductive health problems [7][10]. - Plasticizers, particularly phthalates, are linked to endocrine disruption and various health issues, including obesity and diabetes [9][10]. - Flame retardants, especially halogenated types, can migrate from products into the environment, potentially causing thyroid hormone disruption and neurodevelopmental harm [11][12]. - PFAS are known for their persistence in the environment and human body, associated with liver damage, endocrine disruption, and cancer risks [12][27]. Group 3: Practical Recommendations - To reduce exposure to harmful additives, consumers are advised to check for compliance labels, use products correctly, and avoid plastic containers, especially for food [14][16][17]. - Alternatives to plastic, such as glass, ceramics, and food-grade stainless steel, are recommended to minimize health risks [17].